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Abstract
Th2-driven lung inflammation increases Arginase 1 (Arg1) expression in alternatively-activated macrophages (AAMs). AAMs
modulate T cell and wound healing responses and Arg1 might contribute to asthma pathogenesis by inhibiting nitric oxide
production, regulating fibrosis, modulating arginine metabolism and restricting T cell proliferation. We used mice lacking
Arg1 in myeloid cells to investigate the contribution of Arg1 to lung inflammation and pathophysiology. In six model
systems encompassing acute and chronic Th2-mediated lung inflammation we observed neither a pathogenic nor
protective role for myeloid-expressed Arg1. The number and composition of inflammatory cells in the airways and lungs,
mucus secretion, collagen deposition, airway hyper-responsiveness, and T cell cytokine production were not altered if AAMs
were deficient in Arg1 or simultaneously in both Arg1 and NOS2. Our results argue that Arg1 is a general feature of
alternative activation but only selectively regulates Th2 responses. Therefore, attempts to experimentally or therapeutically
inhibit arginase activity in the lung should be examined with caution.
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Introduction
Host defense against many helminth parasites requires Th2
immunity to kill, expel, or contain pathogens and to repair the
injuries caused by infection. However, inappropriately controlled
Th2 immune responses cause pathology such as the airway
hyperresponsiveness, mucus secretion, inflammation, and lung
remodeling and fibrosis that characterize asthma [1,2]. The Th2
cytokines IL-4 and IL-13, which play a critical role in asthma,
‘‘alternatively’’ activate macrophages and induce receptors,
cytokines, enzymes, and change phagocytosis, proliferation, and
other cellular processes that enable AAMs to regulate their
surrounding leukocytes, parenchymal cells, and environment [3–
5]. Studies testing whether AAMs play a helpful, harmful, or
unimportant role in asthma or other immune-mediated lung
diseases reached contradictory conclusions [6]. Differences in
experimental methods, particularly the choice of antigen and
treatment regimen, likely accounts for some contradictory data,
and negative feedback mechanisms may reconcile apparent
differences if increased gene expression correlates with disease
but inhibits pathology. Nevertheless, immune-modulating asthma
therapies now undergoing clinical trial, such as those targeting IL-
4, IL-13, chemokines, antibody receptors, PPAR-c, or Toll-Like
Receptors, are expected to alter the functions of macrophages
even though it remains unclear what role macrophages play in the
pathogenesis of asthma [7].
In this study we analyzed the role of Arginase 1 (Arg1) expressed
by AAMs in six models of Th2-dominant lung inflammation. We
focused on Arg1 because it is induced in asthma patients and
experimental mouse models, can contribute to or suppress Th2-
mediated pathology by different mechanisms, and represents a
therapeutic target because its enzymatic mechanism is known in
great detail, and existing drugs are known inhibitors of arginases
in vivo [8,9]. Arg1 is one of two enzymes that hydrolyze arginine
to urea and ornithine, and is expressed constitutively by
hepatocytes to play an essential role in the urea cycle [10].
Myeloid lineage cells also express Arg1 but, unlike the constitutive
expression in the liver, myeloid Arg1 is predominantly regulated
by exogenous stimuli [10,11]. A second isoform, mitochondrial
Arg2, is present in many cell types and can also be induced [9].
Compared to Arg1, however, Arg2 expression correlates weakly
with lung inflammation, contributes little to the tissue arginase
activity, and has not been identified as an inducible characteristic
of AAMs [12–14]. Mouse and human arginase expression are not
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exactly matched: in cells isolated from human blood Arg1 has only
been found in neutrophils [15,16] although, importantly, human
tissue macrophages have yet to be rigorously tested for Arg1 or
Arg2 expression.
Two major cytokine pathways control macrophage-specific
Arg1 expression. First, IL-4 and IL-13 induce Arg1 in macro-
phages as part of the IL-4Ra- and STAT6-dependent alternative
activation program. Arg1+ AAMs abound in Th2-dominated
diseases such as asthma, atopic dermatitis, and helminth and other
parasite infections [3]. Second, tuberculosis and other intracellular
bacterial infections trigger Arg1 expression in response to IL-6, G-
CSF and IL-10 stimulation following Toll-like receptor activation
[17,18]. This second pathway requires STAT3 signaling in
response to autocrine/paracrine cytokines but is independent of
the IL-4Ra or STAT6 [18].
Since Th2 responses predominate in asthma and lung and
airway inflammation the IL-4/13-IL-4Ra-Stat6 pathway is
anticipated to drive Arg1 expression in these diseases, and an
increase in Arg1 is associated with many types of lung
inflammation [12,14,19]. These results are intriguing because, if
arginases play a pathologic role in asthma, then arginase inhibitors
might exhibit protective activity against Th2-driven disease
[9,20,21]. Previous studies have accordingly examined arginine
metabolism and tested pharmacological and RNAi-mediated
inhibition of Arg1 in the lung [9,14,22–26] but did not specifically
address the contribution of induced Arg1 expression in myeloid
cells to the pathogenesis of Th2-driven lung inflammation. Set
against these findings, lung pathology was unaffected by deleting
Arg1 in the bone marrow-derived cells of chimeric mice, or in
mice engineered to delete IL-4Ra in Lysozyme M-expressing cells
so that IL-4 and IL-13 could not alternatively active macrophages
and induce Arg1 [13,27].
Here we sought to define essential functions of myeloid Arg1 in
lung and airway inflammation driven by Th2-driven inflamma-
tion. We used genetically engineered mice lacking Arg1 in all
hematopoietic and endothelial cells backcrossed to a C57BL/6 or
BALB/c background [17]. These mice express a transgenic Cre
recombinase under the control of the Tie2 promoter and Arg1
targeted with LoxP sites (hereafter termed "Arg1 KO" for
simplicity). This system offers the significant advantage of efficient
deletion of Arg1 in macrophages, the predominant cell type that
expresses Arg1 outside the liver [11]. Our studies show that Arg1
in AAMs has no impact on the development of lung inflammation.
Materials and Methods
Mice, Genotyping, and Verification of Arg1 Deletion
All experiments performed at the National Institutes of Health
used mice bred and housed under specific pathogen-free
conditions in an American Association for the Accreditation of
Laboratory Animal Care approved facility. The NIAID animal
care and use committee approved all schistosome-related exper-
imental procedures. Experiments performed at St. Jude Children’s
Research Hospital and USCF were approved by the correspond-
ing Institutional Animal Care and Use Committees. The
generation and genotyping of Arg1 KO mice has been described
previously [17]. For schistosome egg and egg antigen experiments,
C57BL/6 Arg1flox/flox; Tie2-cre (Arg1 KO) mice were crossed with
C57BL/6 Nos22/2 mice to generate Arg1flox/flox (wild-type)
controls, Arg1flox/flox; Nos22/2 (iNOS KO) mice, and Arg1flox/flox;
Tie2-cre; NOS22/2 (Arg1/iNOS KO) mice. For OVA, Aspergillus
and NKT cell activation experiments, Arg1flox/flox; Tie2-cre mice
on a BALB/c background (n = 6 generations for each allele) were
used, or these mice were interbred with transgenic BALB/c mice
expressing the chicken ovalbumin 323-339-specific DO11.10
TCR. The genotyping of Arg1-deficiency was initially verified
using immunoblotting from cultured bone marrow macrophages.
Bone marrow was collected at the experimental endpoint and
cultured 7 days in media containing CSF-1. The resulting
adherent macrophages were washed, stimulated overnight with
10 ng/mL each IL-4 and IL-10, and lysed in RIPA buffer. Arg1
was detected in macrophage lysates by immunoblotting with
polyclonal anti-Arg1 antibodies as described [18].
Schistosome Egg-induced Lung Inflammation
Schistosoma mansoni eggs were provided by the Biomedical
Research Institute (Rockville, MD) [28]. For the acute lung
granuloma model, mice were primed with intraperitoneal injection
of 5,000 eggs in PBS, injected intravenously at week 2 with 5,000
live eggs in PBS to induce lung granulomas, and analyzed at week
4. For the repetitive lung granuloma model, primed mice received
weekly i.v. injections of 1,000 live eggs at weeks 2 through 5, then
2,000 live eggs at week 6, and analyzed at week 8. To induce
chronic airway inflammation, mice were injected i.p. with 5,000
eggs at weeks 0 and 2, then anesthetized with ketamine-xylazine
and treated with 8 weekly intratracheal doses of 10 mg Soluble Egg
Antigen, prepared as described [28], from weeks 4 to 11. SEA was
delivered i.t. in 20 mL PBS with a gel loading pipette tip. Mice
were analyzed 1 day after the final dose. Airway-infiltrating cells
were recovered by bronchoalveolar lavage (BAL) with PBS plus
5 mM EDTA. Percentages of cell types were determined using
cytospin preparations stained with Diff-Quick (Boehringer) by
evaluating .200 cells/slide by light microscopy. For histological
analyses, matched lung lobes were washed with PBS, inflated with
Bouin’s fixative, and stained with Wright’s Giemsa. An experi-
enced pathologist scored 6–30 granulomas per mouse (median 20,
mean 20, standard deviation 6.5 for all data presented in Figures 1
and 2) to assess granuloma volume and cellular composition. For
fibrosis, matched lung lobes were weighed and digested with HCl
to measure the quantity of hydroxyproline [29], a characteristic
component of collagens, or sections were stained with picrosirius
red to evaluate collagen distribution. For mucus, fixed lung
sections were stained with the Alcian Blue-Periodic Acid Schiff
reaction to detect mucin polysaccharides associated with epithelial
cells or the airway lumen, and scored by an experienced
pathologist.
Allergen-induced Lung Inflammation
For the ovalbumin model [30] mice were sensitized with i.p.
injections of 50 mg OVA (Sigma-Aldrich) absorbed in 2 mg alum
gel in 200 mL PBS on days 0, 7, and 14, then challenged
intranasally with 100 mg OVA in 40 mL PBS on days 21, 22, and
23. For the Aspergillus model [31], mice received 100 mg of
Aspergillus fumigatus (Hollister-Stier Laboratories) in 40 ml saline 3
times per week for 3 weeks. To measure airway reactivity [30]
mice were anesthetized 24 h (OVA) or 48 h (Aspergillus) after the
last challenge with ketamine (100 mg/kg of body weight), xylazine
(10 mg/kg), and acepromazine (3 mg/kg) and the trachea
cannulated with a 20 gauge tubing adaptor. Mice were attached
to a ventilator and pulmonary mechanics analyzer (FlexiVent) and
ventilated at 9 ml/kg tidal volume, 150 breaths/minute frequency,
and 2 cmH2O positive end-expiratory pressure. Mice were
paralyzed with pancuronium (0.1 mg/kg i.p.) and airway
mechanics were measured continuously using the linear single
compartment model while challenged with escalating doses of
acetylcholine (0.03, 0.1, 0.3, 1 and 3 mg/g i.v.). BAL was
performed via the tracheal cannula. Lungs were washed 3 times
with 1 ml PBS, erythrocytes were lysed, and total BAL cells were
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counted with a hemocytometer. Percentages of cell types were
determined using cytospin preparations stained with HEMA 3
(Fisher) by evaluating .300 cells/slide by light microscopy.
Lavaged lungs were inflated with 10% buffered formalin to
25 cm H2O of pressure and fixed for 1 day. Multiple paraffin-
embedded 5-mm sections of the entire mouse lung were prepared
and stained with Hemotaxylin & Eosin (H&E) to evaluate the
morphology and with Periodic acid-Schiff (PAS) to evaluate mucus
production.
NKT Cell-induced Inflammation
Mice received an intranasal dose of 100 ng PBS57 solubilized in
DMSO plus OVA on day 0, followed by intranasal OVA alone on
days 15, 16, 20 and 21, then sacrificed and analyzed 1 or 2 days
after the final OVA dose. Each group of mice was divided and
used for either BAL or histology.
Immunohistochemistry
Antibody staining for Arg1 in paraffin embedded samples was
optimized by semi-automated methods in the St. Jude Veterinary
Pathology Core. Human liver obtained at autopsy was used as a
positive control for human staining, while mouse livers generated
from Arg12/2 mice were used as a negative control. Antibodies are
described in figure legends.
Arginase and iNOS Activity
Arginase activity was determined by incubating tissue or cell
lysates with L-arginine and measuring urea production, as
Figure 1. Arg1 expression by macrophages does not regulate acute schistosome egg-induced pulmonary granuloma formation and
Th2 response. Mice deficient in Arg1, iNOS, or both enzymes were sensitized by i.p. injection of eggs, then challenged by a single i.v. injection of
eggs to form pulmonary granulomas and analyzed at 2 weeks. A) T lymphocytes (CD3+), macrophages (F4/80+), and Arginase1+ cells were detected
in fixed lung serial sections using immunohistochemistry. Images represent 8 mice of each genotype. B) The volume and eosinophil composition of
10–30 granulomas per mouse were scored in Geimsa-stained lung sections. C) Collagen deposition was compared by measuring L-hydroxyproline in
matched lobes and calculating, by mass, total lung content. D) Expression of Arginase 2 or E) IL-13 mRNA and the Th2-responsive genes RELM-a,
Mucin 5AC, and Gob5 were compared in lung tissue by quantitative PCR, normalized to the mean naı¨ve WT level. F) To evaluate CD4 T cell responses,
lung leukocytes were restimulated with PMA plus ionomycin and stained to detect IL-13, IL-4, IL-5, and IFN-c by flow cytometry. No significant
differences were observed between the challenged groups in B) to F). Results were combined from two independent experiments totaling 11 to 19
mice per group, plus 6 naı¨ve WT controls. Individual mice and group means are shown.
doi:10.1371/journal.pone.0061961.g001
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described [29]. Nitric Oxide Synthase activity was tested using the
Griess reagent to measure nitrite concentrations in cell culture
supernatants, as described [32].
Quantitative PCR
Tissue samples were homogenized in Trizol using a Precellys24
(Bertin Technologies), immediately or after storage in RNAlater.
RNA was extracted with chloroform, isolated with a MagMAX
total RNA isolation kit, and reverse transcribed with Superscript
II. Relative gene expression was measured by quantitative PCR
amplification of cDNA using SYBR Green and an ABI Prism
7900HT Sequence Detection System (all from Life Technologies,
Grand Island, NY) and normalized to RPLP2. All experiments
used intron-spanning primers validated by dissociation curves,
with these sequences: RPLP2 (Fwd TACGTCGCCTCT-
TACCTGCT/Rev GACCTTGTTGAGCCGATCAT), IL13
(CCTCTGACCTTAAGGAGCTTAT/CGTTGCACAGGGGA
GTCT), RELMa (CCCTCCACTGTAACGAAGACTC/CA-
CACCCAGTAGCAGTCATCC), Muc5AC (CAGGACTCTCT-
GAAATCGTACCA/AAGGCTCGTACCACAGGGA), Gob5 (A
GGAAAACCCCAAGCAGTG/GCACCGACGAACTTGATTT
T), Arg1 (GGAAAGCCAATGAAGAGCTG/GCTTCCAACTGC
CAGACTGT), Arg2 (TCCTCCACGGGCAAATTCC/GCTGG
ACCATATTCCACTCCTA), and Nos2 (TGCCCCTTCAATGG
TTGGTA/ACTGGAGGGACCAGCCAAAT).
T Cell Restimulation and Flow Cytometry
Lung leukocytes were isolated from matched washed lobes
crushed through a 100 mm cell strainer, or first minced and
digested with 100 U/mL collagenase D (Sigma-Aldrich) while
rocking for 60–90 at 37u, then underlaid with isotonic 36% Percoll
(GE Healthcare), and centrifuged for 159 at 3506g. Erythrocytes
were eliminated with ACK lysing buffer (Quality Biological). BAL
and lung leukocytes were counted using Trypan blue and a
Cellometer Auto T4 (Nexcelom) or hemocytometer. To analyze
cytokines, T cells were restimulated with 10 ng/mL PMA plus
1 mg/mL Ionomycin for 6 hours with 10 mg/mL Brefeldin A
(Sigma-Aldrich) added for the final 2 hours of culture. Cells were
washed, fixed in 2% paraformaldehyde, stored at 280uC in 10%
DMSO, permeabilized with 0.5% saponin (Sigma-Aldrich) and
stained with antibodies specific for CD4 (clone RM4-5,
eBioscience), IL-4 (11B11, Biolegend), IL-13 (eBio13A,
eBioscience), IL-5 (TRFK5, Life Technologies), and IFN-c
(XMG1.2, eBioscience). Alternatively, restimulated T cells were
stained with Aqua live/dead (Invitrogen), washed, treated with
Foxp3 fixation/permeabilization buffers (eBioscience) and stained
Figure 2. Arg1 expression by macrophages does not regulate
chronic schistosome egg-induced pulmonary granuloma for-
mation and Th2 response. Control and Arg1 KO mice were
sensitized by i.p. injection of eggs, then challenged with 5 weekly
doses of intravenous eggs to repeatedly form pulmonary granulomas
and analyzed 2 weeks after the final challenge. A) The intensity and
location of mucus (AB-PAS) and collagen (picrosirius red) were
compared by histology in stained lung sections. Representative images
of strong mucus production in airways adjacent to granulomas and
dense collagen deposition around the perimeters of granulomas are
shown. B) The volume and eosinophil composition of 6–29 granulomas
per mouse were scored in Geimsa-stained lung sections. C) Cell-
associated mucus around the airways was detected by AB-PAS staining
and scored on a 0–5 point scale. D) Total lung collagen deposition was
assessed by measuring L-hydroxyproline. E) Induction of mRNA
transcription for the Th2-responsive genes RELM-a, Mucin 5AC, and
Gob5 and was tested in lung tissue by quantitative PCR, normalized to
mean expression in naı¨ve WT mice. F) Arginase enzymatic activity was
measured in lung tissue samples from naı¨ve control and egg challenged
mice. No significant differences were observed between challenged WT
and Arg1 KO mice in A) to E). Results are from one experiment including
9 WT and 11 Arg1 KO challenged mice, plus 5 WT and 3 Arg1 KO naı¨ve
controls. Individual mice and group means are shown.
doi:10.1371/journal.pone.0061961.g002
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for Foxp3 (FJK-16S, eBioscience), IL-10 (JES5-16E3, eBioscience),
CD4 (GK1.5, Biolegend), CD45 (30F11, Biolegend), CD8a (53-
6.7, Biolegend), and F4\80 (MF48-21, Invitrogen). Lung macro-
phages were analyzed using Aqua live/dead, Foxp3 buffers, and
staining for CD45, F4\80 (BM8, Biolegend), CD11b (M1/70,
Biolegend), Gr-1 (RB6-8C5, Biolegend), Siglec-F (E50-2440, BD
Biosciences), Mannose Receptor (MR5D3, Biolegend), and
RELM-a (226033, R & D Systems) labeled with Alexa Fluor
488 (Microscale Protein Labeling Kit, Life Technologies). Flow
cytometry was performed using a FACSCanto II (BD Biosciences)
and data were analyzed using FlowJo (Tree Star) using
unstimulated and/or isotype controls of each sample to set gates.
Total or OVA-specific IgE Assay
Sera were obtained from blood collected by cardiac puncture of
antigen- or vehicle-treated mice. Total or OVA-specific IgE serum
levels were measured by ELISA using plates coated with anti-
mouse IgE (Pharmingen R35-72) or OVA. Diluted serum samples
were added to each well, and bound IgE was detected with
biotinylated anti-mouse IgE (Pharmingen, R35-118), streptavidin
conjugated horseradish peroxidase (Pharmingen), and HRP
Figure 3. Arg1 expression by macrophages does not alter chronic SEA-induced airway inflammation. Arg1 KO mice were sensitized to
schistosome eggs then treated with 8 weekly intra-tracheal challenges of soluble egg antigens to provoke chronic airway inflammation and analyzed
1 day after the final dose. A) The intensity and distribution of mucus (AB-PAS) and collagen (picrosirius red) were compared by histology in stained
lung sections. Representative images of mucus-producing airway epithelium and underlying collagen deposition are shown. B) Mucus was visualized
by AB-PAS staining and scored on a 0–5 point scale. C) Total lung collagen deposition was measured using L-hydroxyproline content. D) Induction of
RELM-a, Mucin 5AC, and Gob5, and mRNA in lung tissue was compared by quantitative PCR, normalized to mean expression in naı¨ve mice. E)
Leukocytes from the airways were recovered by broncho-alveolar lavage and categorized by cytospin analysis. Cell numbers did not differ between
WT and Arg1 KO mice (data not shown). F) Lung and airway leukocytes were restimulated with PMA plus ionomycin, stained, and analyzed by flow
cytometry to compare cytokine production by CD4+ T lymphocytes. No significant differences were observed between challenged WT and Arg1 KO
mice. Results were combined from two independent experiments totaling 12 WT and 7 Arg1 KO naı¨ve mice, and 15 WT and 12 Arg1 KO challenged
mice. Individual mice and group means are shown.
doi:10.1371/journal.pone.0061961.g003
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substrate (TMB, BD Biosciences Pharmingen). Results are
expressed as mg/ml IgE.
Statistical Analyses
Statistics were calculated with Prism (GraphPad Software, La
Jolla, CA) applying 1-way ANOVA with Tukey’s multiple
comparisons (Figure 1B), Kruskal-Wallis with Dunn’s post-test
(Figures 1C–F, 2C–F, and 3), Mann Whitney (Figures 2B, S2, and
S3), or 1-way ANOVA with Tukey’s multiple comparisons
(Figure 4). Differences are noted as *(p#0.05), **(p#0.01),
***(p#0.001), or ns (not significant).
Results
The Subset of Arg1-expressing AAMs Cluster Around Th2
Inflammatory Sites
Previous studies discovered that Arg1 plays a protective role
during S. mansoni infection by reducing the immune-mediated
pathology induced when parasite eggs cross the intestinal barrier
or become trapped in the liver, where Arg1+ macrophages
surround the eggs in tightly clustered granulomas [32–34]. In
chronic infections eggs may also become trapped in the lungs,
forming Th2-dependent granulomas, if porto-pulmonary shunts
develop in response to severe liver fibrosis. To investigate the role
of Arg1+ AAMs in Th2-mediated lung pathology, we recreated,
standardized, and synchronized this feature of schistosomiasis by
intravenously injecting a single dose of live parasite eggs into egg-
sensitized mice.
A Th2 immune response characterizes the lung granulomas
surrounding schistosome eggs, with eosinophils, macrophages, and
T lymphocytes forming a spherical inflammatory structure ringed
by activated, collagen-producing fibroblasts (Figure 1A) [35].
While both CD3+ lymphocytes and F4/80+ macrophages were
present throughout the granulomas and lung parenchyma,
macrophages were predominantly localized in the granuloma
centers. We screened anti-Arg1 antibodies for sensitivity and
specificity in stained tissue sections (Figure S1) and evaluated
Arginase 1 expression in lung granulomas by immunohistochem-
istry. Arg1+ cells were also found throughout the lung sections but
concentrated centrally in the granulomas. However, as illustrated
by serial sections, only a subset of the total F4/80+ macrophage
population stained positive for Arg1 and these cells dispropor-
tionately clustered around the eggs in the granuloma cores. This
distinction suggests heterogeneity in the type or activation status of
macrophages even within the microenvironment of a granuloma
dominated by Th2 cytokines.
Arg1 Expression by AAMs does not Regulate
Schistosome Egg-induced Lung Granuloma Formation or
Th2 Responses
To test whether Arg1 plays a protective and immune-
modulating role in the lung, as it does in the liver, we compared
the acute granuloma formation, tissue remodeling and RNA
profiles, and CD4+ T cell responses between WT and Arg1 KO
mice in response to a single challenge with schistosome eggs. The
nearly complete loss of Arg1 staining (Figure 1A) and arginase
enzymatic activity (see below, Figure S2E) confirmed that this gene
was efficiently targeted by Tie2-cre-mediated deletion in our mice
and also, matching results from bone marrow chimera experi-
ments [13], that increased Arg1 expression during lung inflam-
mation derives from hematopoietic cells. Arg2 expression, which
Figure 4. Arg1 expression by macrophages does not affect the outcomes of ovalbumin or Aspergillus-induced allergic airway and
lung inflammation. A) WT and Arg1 KO mice were sensitized and challenged with intranasal Ova, then tested for airway hyper-reactivity. B) Airway-
infiltrating leukocytes were recovered by lavage, counted, and categorized by cytospin analysis. C) Ova-specific serum IgE levels were compared by
ELISA. D, E, F) Equivalent experiments compared the allergic response to Aspergillus. G) Aspergillus-induced lung inflammation was evaluated for
eosinophil recruitment in eosin-stained sections and mucus production in PAS-stained sections. Representative histological images are shown. Except
for the numbers of ovalbumin-induced inflammatory airway leukocytes, no significant differences were observed between challenged WT and Arg1
KO mice. Data represent 1 to 3 independent experiments including .8 mice/group, detailed in Table 1. Group means and standard deviations are
shown.
doi:10.1371/journal.pone.0061961.g004
Table 1. Experimental lung inflammation models performed in this study.
Assay Route # Exp WT mice #Arg1 KO Site
Acute S. mansoni eggs i.v. 2 19 11 NIAID
Eggs i.p. R wk 2 eggs i.v. R wk 4 end
Chronic eggs i.v. 1 9 11 NIAID
Eggs i.p. R wks 2, 3, 4, 5, & 6 eggs i.v. R wk 8 end
Chronic egg antigens i.t. 2 15 12 NIAID
Eggs i.p. R wk 2 eggs i.p. R wks 4, 5, 6, 7, 8, 9, 10, & 11 SEA i.t. R wk 11+ d 1 end
Ovalbumin i.n., aerosol 3 8–10 each 8–10 each St. Jude
i.n. 1 19 20 UCSF
Ova+alum i.p. d 0, 7, & 14 R Ova i.n. d 21, 22, 23 R d 24 end
Aspergillus i.n. 1 20 24 UCSF
Asp i.n. 3X wks 1, 2, & 3 R wk 3+ d 2 end
Ova+PBS57 i.n. 3 8–10 each 8–10 each St. Jude
i.n. 1 12 DO11.10 4 DO11.10 St. Jude
Ova+PBS57 i.n. R Ova i.n. d 15, 16, 20, & 21 R d 22 or 23 end
doi:10.1371/journal.pone.0061961.t001
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could perhaps compensate for the loss of Arg1 activity, did not
change at the tissue mRNA level (Figure 1D).
In contrast to Arg1’s role in the liver and small intestine during
schistosomiasis, we could not detect any distinctions between the
lungs of WT and Arg1 KO mice acutely challenged with the same
eggs and egg antigens (Figure 1). Two weeks after egg injection,
granuloma size, eosinophil recruitment, and collagen deposition
were unaltered by loss of Arg1 in AAMs in the lungs. Lung tissue
mRNA levels of IL-13, and the Th2-inducible genes RELM-a,
Mucin 5AC, and Gob5, all increased to a similar extent in WT
and Arg1 KO mice, as did CD4+ T cell production of IL-13, IL-4,
IL-5, and IFN-c upon restimulation, Although Th2 cytokines
predominated, we noticed elevated IFN-c in T cells and NOS2
mRNA in the lung tissue (data not shown). The mutual
antagonism between Arg1 and iNOS suggested that aberrant
iNOS activity might mask the phenotype of Arg1 deletion. Arg1
deficiency did not alter the number of lung macrophages or
otherwise impair their alternative activation, as assessed by
RELM-a and Mannose Receptor expression, in egg-induced lung
granulomas or egg antigen-induced airway inflammation (Figure
S2). However, Arg1 KO lung leukocytes produced more nitrite
when cultured alone or with LPS plus IFN-c. To test a
confounding role for iNOS in the absence of normal Arg1
expression, in the same experiments we also challenged mice
lacking iNOS or both iNOS and macrophage-derived Arg1.
However, deletion of iNOS or iNOS and Arg1 together revealed
no phenotype (Figure 1).
We reasoned that a single, synchronous round of granuloma
formation might proceed too quickly for Arg1-expressing AAMs to
regulate the response. In Arg1 KO mice infected with S. mansoni,
the early stages of liver inflammation and fibrosis proceed
normally, but chronic egg-induced pathology is exaggerated
because Arg1 negatively regulates persistent Th2 immunity [32].
We therefore treated egg-sensitized WT and Arg1 KO mice with 5
weekly i.v. injections of eggs, to repetitively drive pulmonary
granuloma formation and prolong Th2 inflammation, and
analyzed outcomes 2 weeks after the final dose. Arg1 deficiency
caused no discernible changes in response to this chronic
pulmonary challenge (Figure 2). Repeated egg challenge increased
arginase enzymatic activity in lung tissue ,7-fold over the naı¨ve
baseline, an increase entirely prevented in Arg1 KO mice.
However, negating Arg1 induction did not alter the size and
eosinophil composition of granulomas, collagen content, mucus
production, or mRNA levels of RELM-a, Mucin 5AC, or Gob5,
or in chronically inflamed lungs.
Arg1 Expression by AAMs does not have an Essential
Role in Regulating Chronic Airway Inflammation Induced
by Schistosome Egg Antigens, or by Ovalbumin or
Aspergillus
One consideration for these acute and chronic egg-induced
granuloma experiments is that inflammation initiates at the
endothelial surface because the eggs are trapped within the
pulmonary vasculature. Although this process is a natural feature
of chronic schistosomiasis, lung inflammation triggered by
irritants, allergens, or infections generally originates at the airway
epithelium. To determine whether Arg1 alters chronic airway
inflammation, we sensitized WT and Arg1 KO mice with
schistosome eggs, then challenged them with 8 weekly doses of
intra-tracheal soluble egg antigens (SEA). Even after repetitively
stimulating a Th2-mediated response through the airways we
observed no substantial role for Arg1 in pulmonary immunopa-
thology (Figure 3). Intra-tracheal SEA provoked Arg1-indepen-
dent recruitment of eosinophils and lymphocytes into the airway,
collagen deposition, mucus production, and transcription of the
Th2-responsive genes for RELM-a, Mucin 5AC, and Gob5. Upon
restimulation, lung and airway inflammatory CD4+ T cells
equivalently produced IL-13, IL-4, IL-5, and IFN-c in WT and
Arg1 KO mice. In contrast, the same strain of Arg1-deficient mice
exposed to the same egg antigens by infection in similar time
frames develop an exaggerated Th2 response in the liver and
intestine [32]. From these data, it appears Arg1 expression by
AAMs causes organ-specific regulation of the immune response
against schistosome eggs that reduces pathology in the liver and
intestine but not the lungs.
S. mansoni egg antigens can downmodulate immune responses by
activating Foxp3+ regulatory T cells and inducing IL-10,
ameliorating the pathology of infection and reducing the response
to other antigens in the lung [36–39]. Since this effect might
compensate for Arg1 deficiency we assessed these populations of T
cells in the lungs after challenge (Figure S3). Consistent with prior
studies, both egg-induced lung granulomas and egg antigen-
induced airway challenge recruited inflammatory Foxp3+ and IL-
10+ CD4 T cells, but Arg1 deficiency did not alter these regulatory
T cell populations.
To corroborate our findings, we performed similar allergic
airway sensitization and challenge experiments with widely-
employed antigens: ovalbumin (Ova) and Aspergillus. Ova-treated
WT and Arg1 KO mice developed indistinguishable methacho-
line-induced airway hyperreactivity and elevated Ova-specific
serum IgE levels (Figure 4). Although the composition of airway-
infiltrating leukocytes did not differ, we recovered slightly more
leukocytes from Ova challenged Arg1 KO than WT mice. Intra-
nasal challenge with extracts from Aspergillus fumigates spores caused
airway hyperreactivity and inflammation, IgE production, eosin-
ophil recruitment, and mucus secretion, but control and Arg1 KO
mice responded equivalently in each respect. In addition, we
intensified the immune response to Ova by activating NKT or
both NKT and Ova-specific CD4 T cells. We stimulated cytokine
production from NKT cells using PBS57, a CD1d-binding
glycolipid analog of a-galactosylceramide, while sensitizing mice
to Ova [40]. Subsequent intra-nasal Ova treatment resulted in
eosinophil-rich inflammation throughout the lungs yet without
distinctions between WT and Arg1 KO mice (data not shown). We
also bred control and Arg1 KO mice that expressed the DO11.10
transgenic T cell receptor, so that approximately half their CD4 T
cells would react to Ova. Treatment with PBS57 plus Ova
provoked extensive pulmonary inflammation in these mice but,
again, no apparent Arg1-dependent distinctions (data not shown).
Thus, besides minor differences in the number of airway
leukocytes in one experimental protocol, we find that Arg1
expression by myeloid cells does not regulate pulmonary
immunopathology in six different models of Th2-dependent lung
inflammation.
Discussion
Macrophage-derived Arg1 is not a Key Factor in Murine
Th2 Lung Inflammation and Asthma Models
Arginase inhibition is an appealing and novel strategy to treat
asthma. Arginase activity in the lungs has been associated with
pathology, and existing arginase inhibitors seem relatively non-
toxic and could potentially be administered via aerosol
[20,22,41,42]. Indeed, inhibitor studies in guinea pigs and
siRNA-mediated interference experiments in mice argue that
inhibiting arginases reduces Th2-induced lung pathophysiology
[23,24].
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How might Arg1 regulate asthma and lung inflammation?
Current evidence presented a minimum of four hypothetical and
possibly linked scenarios. (i) Arg1 reduces NO production by
competing with nitric oxide (NO) synthases for arginine, their
common substrate, [43,44] as well as affecting iNOS translation
[45]. Arg1 has a lower affinity for arginine than iNOS, but
competes effectively at a biochemical level because of its faster
catalytic rate [10]. NO plays an important role in airway
physiology, lung inflammation, and host defense, and Arg1 can
inhibit NO production both in vivo and in vitro [17,43,44].
However, macrophages generate NO after upregulating iNOS in
response to TLR and interferon signaling [46]. Since a Th2
response drives asthmatic lung inflammation it seems unlikely that
AAMs in the lung would express substantial iNOS, although this
possibility has not been ruled out. Arg1 could instead indirectly
limit arginine availability to other NOS isoforms expressed by
non-hematopoietic cells in the lung.
(ii) Arg1 can supply metabolites for synthesizing collagen and
polyamines, thereby potentially affecting tissue remodeling. The
arginase reaction yields ornithine, the source of substrate for
proline, which is essential to produce collagens. Ornithine is also
the sole source of substrate for polyamine synthesis [10]. By
regulating these metabolic pathways, Arg1 could cause important
changes in the function, inflammation, remodeling, or fibrosis of
the lung parenchyma and airways. In support of this idea, IL-4/13
stimulates proline production by bone marrow-derived macro-
phages and the availability of ornithine to these AAMs limits
proline output [47].
(iii) Arg1 controls overall arginine bioavailability in the lung
[22]. The amount of arginase activity in vivo depends on elevated
transcription of Arg1, and possibly Arg2, coupled to the rate of
active transport of arginine into cells [9,10]. Expression of one
arginine transporter, CAT2, is also increased by Th2 cytokines
[12], and CAT2-deficient mice spontaneously develop lung
inflammation [48]. Therefore, it is plausible that the rate of
arginine hydrolysis could increase by orders of magnitude in a
local environment as Th2 inflammatory signals coordinately boost
enzyme synthesis, substrate import, and other limiting factors.
Reduced arginine concentrations could limit substrate for NO
synthases in non-myeloid cells as well as alter the metabolic
balance in the lung.
(iv) By depleting arginine Arg1 blocks T cell proliferation. The
importance of this mechanism was demonstrated in chronic
schistosomiasis, an infection causing substantial organ damage but
little mortality. Arg1+ AAMs form granulomas in the liver and
intestine around the parasite eggs and restrain the immune
response against these eggs. If Arg1 is deleted in AAMs,
granuloma size increases, egg-induced pathology becomes lethal,
and, in vitro, AAMs impair T cell proliferation in an Arg1-
dependent mechanism that can be overcome by supplying extra L-
arginine [32,33].
By contrast, here we demonstrate that Arg1 expression by
macrophages plays neither a protective nor pathogenic role in a
diverse range of Th2-mediated lung inflammatory insults. Our
results, taking a genetic approach to generate macrophages devoid
of Arg1, agree with a recently published study where lethally-
irradiated mice reconstituted with Arg1-deficient bone marrow
exhibited normal airway function and lung inflammation [13].
Since irradiation has a profound effect of normal lung function
[49], it was possible that additional Arg1-independent effects may
have obscured the outcomes of Th2-driven inflammation in that
setting. Thus, our genetic-based data substantiate the results of
Neise et al [13]. Although arginase inhibitors affect both Arg1 and
Arg2 [9,41,42], Arg1 expression by hematopoietic cells accounts
for allergen-induced increased in arginase activity in the lungs, and
eliminating Arg2 had no effect [13]. Furthermore, we found that
eliminating iNOS in combination with Arg1 also had little effect,
suggesting that the Arg1-iNOS nexus in macrophages is dispens-
able for all obvious phenotypes of Th2-driven lung inflammation.
Accordingly, we argue that drugs targeting arginases in the lung
should be evaluated with considerable caution.
Inhibitory Effects of Macrophage-derived Arg1 in Th2
Responses are Organ-specific
Our results with lung inflammation models, including schisto-
some egg and egg antigen-induced inflammation, are strikingly
juxtaposed to Arg1’s essential role in enabling macrophages to
restrain the hepatic and intestinal Th2 response in schistosome-
infected mice [32,33]. In all three tissues Arg1-positive AAMs
surround the egg and interact with T cells in a granuloma
microenvironment. In the liver, however, Arg1-positive macro-
phages suppress excessive Th2 responses (and perhaps other types
of T cell responses [33]), decreasing granuloma size, fibrosis, and
hepatomegaly, and even preventing death. Since Arg1-expressing
macrophages restrict T cell proliferation in vitro and in schisto-
some-infected mice [32,33], we hypothesized that arginine
depletion by AAMs might function as a feedback mechanism for
regulating immunity. Th2 immune responses recruit and alterna-
tively activate macrophages, increasing arginase activity, decreas-
ing arginine availability, and therefore enabling Arg1 to control T
cell proliferation and function within a localized tissue environ-
ment [50]. In the lungs, by contrast, we observed no differences in
T cell phenotype in Arg1 KO mice even though the immune
response to eggs in the lungs is ostensibly identical to that in the
liver.
We hypothesize that organ differences in Arg1 function depend
on the rate and/or magnitude of circulating arginine. Liver tissue
has high cellular density, high baseline arginase activity, and, by
late stage schistosomiasis, severely impaired perfusion. In contrast,
even chronically inflamed lung tissue has (compared to liver) low
cellular density, low arginase activity, and largely intact perfusion,
which to us seems a plausible explanation for why T cells in the
lung do not experience arginine deprivation that triggers cell cycle
arrest. While simplistic, this concept may predict the environments
where arginine deprivation impacts immunity and pathology: in
the liver, kidney, and small intestine where parenchymal arginase
activity is high, in solid tumors infiltrated with myeloid-derived
suppressor cells, and in fibrotic tissues (Figure S4). Analogous
predictions may apply to depletion of other critical metabolites,
such as tryptophan and cysteine. At this stage, however, the
technical requirements for measuring the quantity of free arginine
available for uptake by cells within tissue microenvironments
prevents direct testing of this hypothesis.
Why is Arg1 Induced by Macrophages in the Th2-
inflammed Lung if it is not Required?
It is important to consider that Arg1 is only one of the suite of
genes induced in AAM, and AAM are only one element of the
immune response coordinated by Th2 cytokines [11]. IL-4 and IL-
13 induce a predictable pattern of gene expression in macrophag-
es, regardless of the associated infection or disease [3]. Increased
Arg1 is considered a canonical marker for mouse AAMs and is
found in virtually every scenario where Th2 cytokines stimulate
macrophages [11]. Recent data prove that Arg1 can also be
expressed in macrophages in many contexts distinct from a Th2
response [17,18]. Thus, while mouse AAM express Arg1, not all
Arg1 positive macrophages are alternatively activated.
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Since Th2-driven AAM gene expression response is apparently
activated regardless of the infection or insult, some of these genes
may not play important roles in every situation. Mice with a
selective deletion of the IL-4Ra in macrophages mount a normal
CD4+ T cell Th2 response but, since their macrophages cannot
bind IL-4 or IL-13, they specifically lack AAMs. Infection of these
mice demonstrated that AAM critically affect immune reactions to
schistosomes, but are dispensable for immunity to the parasitic
nematode Nippostronglyus brasiliensis, which is also controlled by a
Th2 response [51]. Such differences may be explained if it is
favorable to elicit the entire AAM gene expression profile even
though only a subset (or one) gene product is necessary for effective
macrophage-mediated immunity. Thus, we argue that increased
expression of Arg1 in macrophages during asthma and lung
inflammation is a consequence of a pre-set activation program
necessary to combat a wide variety of parasites (especially worms)
in a tissue-specific way. In some cases, Arg1 is obligatory for
immunity or to protect the host but, in other situations, other Th2-
induced gene products may be needed.
Furthermore, Th2-induced genes that distinguish AAMs from
macrophages in different activation states can also be upregulated
by other cell types [3]. Redundant or compensatory expression of
key molecules by multiple cell types could explain why allergic
airway disease was recently and, to us, surprisingly, found to be
unaffected in LysM-Cre IL-4RaFlox mice in which macrophages
cannot be activated by IL-4 or IL-13 [27]. For Arg1, we suggest
that expression by fibroblasts might prove important for lung
disease, since cell intrinsic arginase activity could promote fibrosis
via proline to collagen and polyamine synthesis. This hypothesis
may explain why deleting Arg1 in macrophages does not alter
Th2-mediated lung inflammation or pathology while arginase
inhibitors or siRNA nonetheless ameliorate some features of
asthma.
Our results demonstrate that a major obstacle to understanding
the roles of AAMs will be distinguishing correlation from
causation. Indeed, detecting associations between Arg1, or any
other IL-4/13-stimulated gene in macrophages, and host defense
or immunopathology merely demonstrates a Th2 immune
response. Only by testing putative macrophage effector function
genes one at a time against a variety of challenges will we gain a
full understanding of the overall complexity and robustness of the
AAM response.
However, the heterogeneity within macrophages populations
offers an alternative experimental approach. In this study, we
anticipated that nearly all macrophages inside a Th2-derived
granuloma would express Arg1. Instead, even within this
inflammatory microenvironment, most macrophages appear not
to express Arg1 unless located at the core, near the schistosome
egg. Our data suggest that, even over very short distances,
macrophages have differential access to IL-4, IL-13, and other
activation signals. Careful dissection of the combinations of
macrophage-activating signals offers a complementary and poten-
tially more productive strategy than iterating the approach we took
with Arg1 with every interesting gene STAT6 induces in
macrophages.
Supporting Information
Figure S1 Evaluation of anti-Arg1 antibodies. The
sensitivity and specificity of commercially available mono- and
polyclonal anti-Arg1 antibodies were tested by immunohistochem-
ical staining of fixed human and mouse liver sections. We selected
the sc-20150 anti-mouse Arg1 antibody for use in experiments
after comparing the staining intensities of hepatocytes (positive
control), liver endothelium (no Arg1 expression), and entirely
Arg1-deficient mouse liver (negative control).
(TIF)
Figure S2 Effects of Arg1 deficiency on macrophage
phenotypes. Control and Arg1 KO mice were sensitized by i.p.
injection of eggs, then challenged with either intravenous eggs to
induce lung granulomas or intra-tracheal SEA to cause airway
inflammation. Leukocytes were isolated from perfused and
digested lungs, and macrophages were analyzed by flow
cytometry. Macrophages were identified by gating on live
CD45+ Siglec F(neg/low) Gr1(neg/low) F4\80+ CD11b+ events
and stained for RELM-a and mannose receptor expression, as
markers of alternative activation. Representative samples of A) d8
lung granuloma and B) d7 airway SEA mice challenged on d0 and
d6 are shown. C) Percentages and numbers of macrophages, and
D) expression levels of RELM-a and mannose receptor were
calculated for group means and individual mice. Alternatively,
lung leukocytes were cultured overnight with no added stimula-
tion, 20 ng/mL IL-4, or 2 mg/mL LPS plus 20 ng/mL IFN-c. E)
Arginase activity was measured in cell lysates by urea production
and F) iNOS activity was measured by nitrite production in
culture supernatants, normalized to the input number of
macrophages and shown as group means and standard deviations.
(PDF)
Figure S3 Effects of Arg1 deficiency on regulatory CD4+
T lymphocytes. Control and Arg1 KO mice were sensitized and
challenged as described in Figure S2. Lung leukocytes were
stimulated with PMA, Ionomycin, and Brefeldin A, or cultured
with Brefeldin A alone, and analyzed by flow cytometry. CD4+ T
cells were identified by gating on live CD45+ CD4+ CD8a(neg)
F4\80(neg) events and stained for Foxp3 and IL-10 expression.
Representative samples of A) d8 lung granuloma and B) d7 airway
SEA mice challenged on d0 and d6 are shown. C) Numbers of
CD4 T lymphocytes and percentages of Foxp3+ cells, and D) IL-
10 expression by Foxp3(neg) and Foxp3+ CD4+ T lymphocytes
were calculated for group means and individual mice.
(PDF)
Figure S4 Arginase activity in different tissues. Samples
of liver, kidney, small intestine (subdivided into duodenum,
jejunum, and ileum), colon, lung, spleen, and mesenteric lymph
nodes were taken from 4 perfused naive mice. Tissue arginase
activity was measured by urea production.
(TIF)
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